Literature DB >> 4053486

Mephenytoin hydroxylation polymorphism: characterization of the enzymatic deficiency in liver microsomes of poor metabolizers phenotyped in vivo.

U T Meier, P Dayer, P J Malè, T Kronbach, U A Meyer.   

Abstract

The rate of 4-hydroxylation and of N-demethylation of S- and R-mephenytoin was determined in liver microsomes of 13 extensive (EM) and two poor (PM) metabolizers of mephenytoin. Detailed kinetic studies were performed in microsomes of eight EMs and the two PMs. Microsomal mephenytoin metabolism in PMs was characterized by an increased Km (150.6 and 180.6 vs. a mean [+/- SD] 37.8 +/- 9.6 mumol/L S-mephenytoin in 8 EMs), a decreased maximum rate of metabolism for S-mephenytoin hydroxylation (0.76 and 0.69 vs 4.85 +/- 1.65 nmol 4-hydroxymephenytoin per milligram protein per hour), and loss of stereoselectivity for the hydroxylation of the R- and S-enantiomers of mephenytoin (R/S ratio: 1.10 and 0.76 vs. 0.11 +/- 0.04 in 13 EMs). The formation of 4-OH-mephenytoin from R-mephenytoin and the demethylation reaction remained unaffected. These results support our hypothesis that the mephenytoin polymorphism is caused by a partial or complete absence or inactivity of a cytochrome P-450 isozyme with high affinity for S-mephenytoin.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4053486     DOI: 10.1038/clpt.1985.213

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  11 in total

1.  Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics.

Authors:  L M Forrester; C J Henderson; M J Glancey; D J Back; B K Park; S E Ball; N R Kitteringham; A W McLaren; J S Miles; P Skett
Journal:  Biochem J       Date:  1992-01-15       Impact factor: 3.857

2.  Lack of defect in oxidative hydroxylation of debrisoquine in a patient with halothane hepatitis.

Authors:  M Toutoungi; D Magnenat
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 3.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

4.  Limitation to the use of the urinary S-/R-mephenytoin ratio in pharmacogenetic studies.

Authors:  Y Zhang; R A Blouin; P J McNamara; J Steinmetz; P J Wedlund
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

5.  In vitro metabolism of the biguanide antimalarials in human liver microsomes: evidence for a role of the mephenytoin hydroxylase (P450 MP) enzyme.

Authors:  N A Helsby; S A Ward; R E Howells; A M Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1990-08       Impact factor: 4.335

6.  Mephenytoin stereoselective elimination in the rat: III. Stereoselective time course of induction during chronic hepatic portal vein administration.

Authors:  S H Akrawi; P J Wedlund
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Jul-Sep       Impact factor: 2.441

7.  Comparison of (S)-mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms.

Authors:  J K Coller; A A Somogyi; F Bochner
Journal:  Br J Clin Pharmacol       Date:  1999-08       Impact factor: 4.335

8.  In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-mephenytoin hydroxylase.

Authors:  D J Birkett; D Rees; T Andersson; F J Gonzalez; J O Miners; M E Veronese
Journal:  Br J Clin Pharmacol       Date:  1994-05       Impact factor: 4.335

9.  Characterisation of theophylline metabolism in human liver microsomes.

Authors:  R A Robson; A P Matthews; J O Miners; M E McManus; U A Meyer; P M Hall; D J Birkett
Journal:  Br J Clin Pharmacol       Date:  1987-09       Impact factor: 4.335

10.  Relationship between mephenytoin oxidation polymorphism and phenytoin, methylphenytoin and phenobarbitone hydroxylation assessed in a phenotyped panel of healthy subjects.

Authors:  J H Schellens; J H van der Wart; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1990-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.